News | May 12, 2021
Dr. Reddy's launches Ertapenem in US
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
The Department of Pharma has allocated this drug amongst the states/UTs based on expected supply that will be available from May 10 to May 31, 2021
Favipiravir is close to Remdesivir, Remdesivir is used to treat moderate to severe cases while Favipiravir is used to treat mild to moderate cases
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
State governments and UTs have been asked to monitor proper distribution within the state/UT covering government and private hospitals
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
This Emergency Use Authorisation will now enable Roche to import the globally manufactured product batches to India
The facility is expected to be completed in 2024
Subscribe To Our Newsletter & Stay Updated
